LEADER 03612nam  22006015  450 
001 9910300181103321
005 20200701222803.0
010   $a3-319-17362-6
024 7 $a10.1007/978-3-319-17362-7
035   $a(CKB)3710000000449534
035   $a(EBL)3567780
035   $a(SSID)ssj0001534784
035   $a(PQKBManifestationID)11824413
035   $a(PQKBTitleCode)TC0001534784
035   $a(PQKBWorkID)11495834
035   $a(PQKB)11408486
035   $a(DE-He213)978-3-319-17362-7
035   $a(MiAaPQ)EBC3567780
035   $a(PPN)187684677
035   $a(EXLCZ)993710000000449534
100   $a20150716d2015      u|         0
101 0 $aeng
135   $aur|n|---|||||
181   $ctxt
182   $cc
183   $acr
200 10$aMuscular Dystrophy $eA Concise Guide /$fedited by Raymond A. Huml
205   $a1st ed. 2015.
210  1$aCham :$cSpringer International Publishing :$cImprint: Springer,$d2015.
215   $a1 online resource (206 p.)
300   $aDescription based upon print version of record.
311   $a3-319-17361-8 
320   $aIncludes bibliographical references at the end of each chapters and index.
327   $a1. Introduction to Muscular Dystrophy -- 2.Muscular Dystrophy: Historical Background and Types -- 3.FSHD: The Most Common Type of MD? -- 4.Duchenne and Becker Muscular Dystrophies: Underlying Genetic and Molecular Mechanisms -- 5.An Overview of the Muscular Dystrophies: Underlying Genetic and Molecular Mechanisms -- 6.Transition from Childhood to Adult in Patients with Muscular Dystrophy -- 7.Overview of Current Treatments for Muscular Dystrophy -- 8.Physical Therapy and Orthotic Devices for Patients with Muscular Dystrophy -- 9.Orthopedic Care of Children with Muscular Dystrophy -- 10.Global Regulatory Landscape -- 11.Key Challenges to the Approval of Products to Treat Patients with Muscular Dystrophy -- 12.Pharmaceutical Products and Non-Pharmaceutical Interventions as Potential Treatments for Patients with Muscular Dystrophy -- 13.US Patient Advocacy Groups -- 14.Global and National Patient Registries -- 15.Summary -- Index.
330   $aThis practical and concise guide offers an overview of muscular dystrophy's (MD) complicated features, treatment options and general resources.  New treatments and a greater understanding of proteins and structures associated with MD are discussed along with long-term patient care.  Also included are clinical and developmental challenges within the current regulatory landscape and recent scientific and clinical advances.  Muscular Dystrophy: A Concise Guide offers clinicians, researchers, pharmaceutical executives and patient advocacy groups an easy-to-read reference that provides the necessary perspectives of the care giver and patient.
606   $aNeurology 
606   $aPharmacotherapy
606   $aMedicine
606   $aNeurology$3https://scigraph.springernature.com/ontologies/product-market-codes/H36001
606   $aPharmacotherapy$3https://scigraph.springernature.com/ontologies/product-market-codes/H69000
606   $aMedicine/Public Health, general$3https://scigraph.springernature.com/ontologies/product-market-codes/H00007
615  0$aNeurology .
615  0$aPharmacotherapy.
615  0$aMedicine.
615 14$aNeurology.
615 24$aPharmacotherapy.
615 24$aMedicine/Public Health, general.
676   $a610
702   $aHuml$b Raymond A$4edt$4http://id.loc.gov/vocabulary/relators/edt
906   $aBOOK
912   $a9910300181103321
996   $aMuscular Dystrophy$92245862
997   $aUNINA